Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 8/20 | 0.44 |
| ▸ | CYP3A5 | P20815 | 5/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4460408 | 0.92 | NFE2L2 (0.42) | CYP3A4CYP3A5TAAR1PTGS1PTGS2 | |
| SCHEMBL4464155 | 0.91 | TAAR1 (0.40) | CYP3A4CYP3A5CYP19A1TAAR1PTGS1 | |
| SCHEMBL4457222 | 0.90 | TAAR1 (0.43) | TAAR1PTGS2LRRK2ALDH1A1 | |
| SCHEMBL4460584 | 0.89 | TAAR1 (0.44) | TAAR1PTGS2LRRK2KDM4C | |
| SCHEMBL4461901 | 0.89 | CYP3A4 (0.52) | CYP3A4CYP3A5CYP19A1PTGS1PTGS2 | |
| SCHEMBL4472068 | 0.89 | TAAR1 (0.39) | CYP3A4CYP3A5TAAR1PTGS1PTGS2 | |
| SCHEMBL4461909 | 0.89 | TAAR1 (0.39) | CYP3A4CYP3A5TAAR1PTGS1PTGS2 | |
| SCHEMBL4456792 | 0.88 | CYP3A4 (0.44) | CYP3A4CYP3A5PTGS1PTGS2NFE2L2 | |
| SCHEMBL4458283 | 0.88 | KCNA5 (0.44) | CYP3A4TAAR1PTGS2LRRK2KDM4C | |
| SCHEMBL4472842 | 0.86 | TAAR1 (0.40) | CYP3A4TAAR1PTGS1PTGS2LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090030043-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2009-01-29 | — | — | US | claimed |
| EP-1981507-A2 | POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2008-10-22 | — | — | EP | claimed |
| WO-2007089679-A2 | POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2007-08-09 | — | — | WO | claimed |
| US-20090030043-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2009-01-29 | — | — | US | disclosed |
| EP-1981507-A2 | POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007089679-A2 | POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007089679-A2 | POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030043-A1 | Potassium Channel Inhibitors | KCNJ2, KCNH2, KCNH3 | CYP3A4 1307/4885CYP3A5 902/4885CYP19A1 4359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.